Here is David’s bio, from the AVP website:
Over the last decade, Nathaniel David has co-founded four biotechnology companies that have collectively raised more than $450 million in financing. Teaming with ARCH in 2009, Dr. David is building new companies that create disruptive technologies to address global-scale problems.
During the last year of his doctoral work at the University of California, Berkeley, he co-founded Syrrx (acquired by Takeda for $270 million in 2005) and then co-founded Achaogen a few years later. Teaming up with a group of former Amgen employees, he co-founded Kythera Biopharmaceuticals where he served for four years as Chief Science Officer, a role in which he managed all pre-clinical drug discovery efforts. During his tenure, two first-in-class therapies (ATX-101 and ATX-104) entered human clinical trials.
In the clean technology arena, Dr. David is co-founder of Sapphire Energy, a biotechnology-driven energy company developing next generation fuels that are 100% compliant with the current fuel infrastructure.
Dr. David holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, and aesthetic medicine. He serves on the board of directors of Sapphire Energy and Kythera Biopharmaceuticals and is a member of the board of trustees of the University of California Foundation. Dr. David was named one of the Top 100 innovators in the world under 35 by the MIT Technology Review in 2002.
Dr. David holds a Ph.D. from the University of California, Berkeley in Molecular and Cellular Biology and an A.B. in Biology from Harvard College.